GLP-1 Drugs May Confer Reduced Uveitis Risk

GLP-1 receptor agonists have been shown to reduce oxidative stress and modulate T-cell activity, likely contributing to systemic anti-inflammatory effects. Photo: Novo Nordisk. Click image to enlarge. Glycemic control in diabetes has been revolutionized with the recent widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists. Interestingly, this drug class, although primarily used for metabolic control, may also possess anti-inflammatory properties, prompting investigators to further explore this prospect.In a new study published yesterday in JAMA Ophthalmology, researchers looked at retrospective electronic health record network data comprising patients with and without diabetes who received prescriptions for GLP-1 drugs, metformin, insulin or sodium-glucose cotransporter 2 inhibitors (SGLT2i). The control groups served as patients who did not have a prescription for each drug.The total patient count was 516,052 individuals. When compared with controls, the GLP-1 cohort had reduced uveitis risk, and this stayed consistent for those with type 2 diabetes and those without, as well as across different uveitis subtypes. Overall, this cohort exhibited a 51.7% reduction of risk. GLP-1 agonist prescriptions were also associated with greater protection against uveitis than that seen in those who took metformin or insulin. However, GLP-1 drugs were associated with a slightly higher rate of uveitis when compared with SGLT2i agents, which also conferred a reduced uveitis risk when compared with controls.The study researchers relay that the possible anti-inflammatory effects likely stem from mechanisms of altering cytokine levels. GLP-1 receptor agonists may decrease the production of proinflammatory cytokines, thereby reducing uveitis risk. Conversely, they have already been shown to promote production of the anti-inflammatory cytokine interleukin-10, which could exert a protective effect against noninfectious versions of the condition.Another related mechanism is that the drug class could reduce uveitis risk through promotion of weight loss, since obesity is known to increase risk of various autoimmune disorders. This is due to adipose tissue producing higher levels of proinflammatory cytokines, thus adding to a chronic, subclinical inflammatory state.The authors summarize how the drugs’ potential to reduce systemic and ocular inflammation may translate into real-world considerations: “Patients with a history of autoimmune or rheumatologic conditions, a family history of uveitis, or a strong genetic predisposition may particularly benefit,” they wrote. For patients already meeting indications for use of a GLP-1 drug based on metabolic factors, “its potential role in lowering uveitis risk could be an added consideration when selecting antihyperglycemic therapy.”1While these possibilities are positive advancements, a commentary on the study, also published yesterday in JAMA Ophthalmology, provides some potential limitations to keep in mind when interpreting conclusions.The commentators point out that the research may not be fully accounting for a persistent imbalance in HbA1c levels in subjects and BMI may tend toward bias in prescribing patterns for these drugs, despite using propensity score matching. That is, GLP-1 agonists are more commonly prescribed to those with severe metabolic fluctuations—including higher BMI and worse glycemic control—which are factors that could by themselves influence uveitis risk, as there may be a link between elevated HbA1c and increased ocular inflammation risk.What’s more, the commentary points out, propensity score matching cannot account for changes of variables over time, such as in glycemic control, BMI or treatment adherence. As the authors explain, these factors are quite important in chronic diseases like diabetes, in which trajectories and therapeutic responses vary.Succinctly said, the commentators believe that “for now, the study serves as a valuable hypothesis-generating endeavor and highlights that evolving interface between metabolic therapeutics and ocular immunology.”2Click here for the study and here for the commentary. 1. Mohan N, Srivastava SK, Schulgit MJ, et al. Glucagon-like peptide-1 receptor agonists and risk of uveitis. JAMA Ophthalmol. August 28, 2025. [Epub ahead of print].2. Toy BC, Hong AT. Uveitis risk and GLP-1RA use—signal, confounding, or both? JAMA Ophthalmol. August 28, 2025. [Epub ahead of print]. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.